TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - CRISPR THERAPEUTICS Share Price

Certificat

DE000SU91T11

Market Closed - Börse Stuttgart 08:35:13 17/05/2024 BST
5.47 EUR +2.63% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - CRISPR THERAPEUTICS
Current month-3.01%
1 month+1.67%
Date Price Change
17/05/24 5.47 +2.63%
16/05/24 5.33 -2.74%
15/05/24 5.48 -0.54%
14/05/24 5.51 -6.77%
13/05/24 5.91 +3.87%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 08:35 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying CRISPR THERAPEUTICS AG
IssuerLogo Issuer Société Générale Société Générale
WKN SU91T1
ISINDE000SU91T11
Date issued 29/02/2024
Strike 114.9 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.55
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.91
Lowest since issue 2.49

Company Profile

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Sector
-
More about the company

Ratings for CRISPR Therapeutics AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: CRISPR Therapeutics AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
56.22 USD
Average target price
86.78 USD
Spread / Average Target
+54.36%
Consensus